172 related articles for article (PubMed ID: 38299551)
21. Anti-tumor necrosis factor-α therapy in uveitis.
Cordero-Coma M; Sobrin L
Surv Ophthalmol; 2015; 60(6):575-89. PubMed ID: 26164735
[TBL] [Abstract][Full Text] [Related]
22. Miliary tuberculosis developing during adalimumab treatment for Behçet's disease with uveitis.
Kim MJ; Jones N; Steeples LR
BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567192
[TBL] [Abstract][Full Text] [Related]
23. TNF inhibition for ophthalmic indications: current status and outlook.
Rifkin LM; Birnbaum AD; Goldstein DA
BioDrugs; 2013 Aug; 27(4):347-57. PubMed ID: 23568177
[TBL] [Abstract][Full Text] [Related]
24. PAPA Syndrome: Challenges in Achieving Long-Term Remission.
Smajlović H; Prohić A
Acta Dermatovenerol Croat; 2023 Nov; 31(2):106-109. PubMed ID: 38006373
[TBL] [Abstract][Full Text] [Related]
25. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
[TBL] [Abstract][Full Text] [Related]
26. Drug survival of the infliximab biosimilar (CT-P13) in paediatric patients with non-infectious uveitis.
Sözeri B; Kardeş E; Salı E; Çakır D; Demir F
Clin Exp Rheumatol; 2021; 39(4):907-912. PubMed ID: 33635217
[TBL] [Abstract][Full Text] [Related]
27. Profile of adalimumab and its potential in the treatment of uveitis.
Balevic SJ; Rabinovich CE
Drug Des Devel Ther; 2016; 10():2997-3003. PubMed ID: 27698552
[TBL] [Abstract][Full Text] [Related]
28. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
[TBL] [Abstract][Full Text] [Related]
29. [Research update of anti-TNF-α biologic agents in the treatment of uveitis].
Fan F; Zhou M; Luo Y
Zhonghua Yan Ke Za Zhi; 2013 Mar; 49(3):285-8. PubMed ID: 23866712
[TBL] [Abstract][Full Text] [Related]
30. Response of pediatric uveitis to tumor necrosis factor-α inhibitors.
Lerman MA; Burnham JM; Chang PY; Daniel E; Foster CS; Hennessy S; Jabs DA; Joffe MM; Kaçmaz RO; Levy-Clarke GA; Mills MD; Nussenblatt RB; Rosenbaum JT; Suhler EB; Thorne JE; Kempen JH
J Rheumatol; 2013 Aug; 40(8):1394-403. PubMed ID: 23818712
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults.
Borrás-Blasco J; Casterá DE; Cortes X; Abad FJ; Rosique-Robles JD; Mallench LG
Int J Clin Pharmacol Ther; 2015 May; 53(5):377-90. PubMed ID: 25345430
[TBL] [Abstract][Full Text] [Related]
32. Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis.
Renton WD; Jung J; Palestine AG
Cochrane Database Syst Rev; 2022 Oct; 10(10):CD013818. PubMed ID: 36239193
[TBL] [Abstract][Full Text] [Related]
33. Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice.
Armuzzi A; Bouhnik Y; Cummings F; Bettey M; Pieper B; Kang T
Dig Liver Dis; 2020 Nov; 52(11):1259-1265. PubMed ID: 32601035
[TBL] [Abstract][Full Text] [Related]
34. Anti-Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis Network.
Leclercq M; Andrillon A; Maalouf G; Sève P; Bielefeld P; Gueudry J; Sené T; Moulinet T; Rouvière B; Sène D; Desbois AC; Domont F; Touhami S; El Chamieh C; Cacoub P; Bodaghi B; Biard L; Saadoun D
Ophthalmology; 2022 May; 129(5):520-529. PubMed ID: 34793830
[TBL] [Abstract][Full Text] [Related]
35. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease.
Reinisch W; Gecse K; Halfvarson J; Irving PM; Jahnsen J; Peyrin-Biroulet L; Rogler G; Schreiber S; Danese S
Inflamm Bowel Dis; 2021 Jan; 27(1):106-122. PubMed ID: 32634212
[TBL] [Abstract][Full Text] [Related]
36. Recommendation of using systemic anti-tumor necrosis factor-alpha for the treatment of noninfectious uveitis in Taiwan.
Hwang DK; Hwang YS; Tsai ML; Lin CJ; Chan WC; Chang YC; Chen DY; Hsieh TY; Sheu SJ; Lin CP
Taiwan J Ophthalmol; 2018; 8(3):117-120. PubMed ID: 30294525
[TBL] [Abstract][Full Text] [Related]
37. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review.
Rosenbaum JT; Bodaghi B; Couto C; Zierhut M; Acharya N; Pavesio C; Tay-Kearney ML; Neri P; Douglas K; Pathai S; Song AP; Kron M; Foster CS
Semin Arthritis Rheum; 2019 Dec; 49(3):438-445. PubMed ID: 31301816
[TBL] [Abstract][Full Text] [Related]
38. New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview.
Valenzuela RA; Flores I; Urrutia B; Fuentes F; Sabat PE; Llanos C; Cuitino L; Urzua CA
Front Pharmacol; 2020; 11():655. PubMed ID: 32508634
[TBL] [Abstract][Full Text] [Related]
39. Anti-TNF-α agents for refractory cystoid macular edema associated with noninfectious uveitis.
Schaap-Fogler M; Amer R; Friling R; Priel E; Kramer M
Graefes Arch Clin Exp Ophthalmol; 2014 Apr; 252(4):633-40. PubMed ID: 24366669
[TBL] [Abstract][Full Text] [Related]
40. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
